Delivering unparalleled reach and expertise for vaccine clinical trials worldwide
Velocity has conducted trials that have led to nine vaccine approvals in the past three years
The Velocity Vaccine Council to Accelerate Research Excellence (CARE) provides world-class operational, recruitment, and trial conduct oversight for all Velocity sites conducting infectious disease studies.
Global leadership: As the world’s site leader in infectious disease research, Velocity excels in both high-volume trials and specialized trials that require hard-to-reach patients. Velocity’s diverse global footprint supports rapid enrollment, even for studies involving sensitive cohorts (e.g., seniors, children, pregnant women, at-risk populations).
Unparalleled expertise: The Vaccine CARE Council is led by Principal Investigators with extensive research and medical practice experience. Beyond ensuring all Velocity sites meet best practices established by world-class vaccine researchers, several Velocity investigators are also sought after by Sponsors and CROs to review protocols and guide effective study design.
Trusted performance: Velocity is the partner-of choice for many of the world’s leading Sponsors and CROs. Velocity investigators enrolled the first U.S. participants in Phase 2 and 3 COVID-19 vaccine trials, and frequently author articles and report trial results in prestigious industry journals.
Reach and capabilities
- 60+ Velocity Vaccine CARE Council sites worldwide
- 100+ investigators with vaccine research experience
- Access to millions of patient lives
- World-class diversity and community engagement initiatives
- On-site lab and PBMC processing capabilities
- Support for novel vaccines, antiviral drugs, diagnostics, and combination products
A transformative model to confront the inefficiencies that plague clinical trials
1: Drug Development Technology. (2012). Clinical trial delays: America’s patient recruitment dilemma. | 2: Tufts Center for the Study of Drug Development. (2013). Impact report: 89% of trials meet enrollment, but timelines slip, half of sites under-enroll. Vol. 15, No. 1. | 3: Kaitin, K. I. (2006). Fastest drug developers consistently best peers on key performance metrics. Tufts Center for the Study of Drug Development Impact Report, 8(5). | 4: Hess, J. (n.d.). Web-based patient recruitment: best opportunity to accelerate clinical trials.
When outcomes depend on the experience of your investigators and research staff, Velocity is the partner of choice
Trial experience
- Anthrax
- Avian Influenza
- Botulinum
- C. difficile (C-diff)
- Celiac Disease
- Chikungunya
- COVID-19 (SARS-CoV-2)
- Cytomegalovirus
- Dengue Fever
- Diphtheria
- Ebola
- E. coli
- Encephalitis
- Epstein-Barr Virus (EBV)
- Group B Streptococcus
- Hepatitis B
- Herpes Zoster (Shingles)
- HIV
- Human Metapneumovirus
- Human Papillomavirus
- Influenza (H1N1, H5N1, H7N1, H7N9)
- Lyme Disease
- Meningococcal Disease
- MMR (Measles, Mumps, Rubella)
- mRNA Vaccines
- Norovirus
- Parainfluenza
- Pediatric Influenza
- Pediatric Meningitis
- Pertussis (Whooping Cough)
- Plague
- Pneumococcal Disease
- Rabies
- Respiratory Syncytial Virus
- Smallpox
- Staphylococcus
- Tetanus
- Type 3 Parainfluenza Virus (PIV3)/RSV Combo
- Varicella
- West Nile Virus
- Yellow Fever
- Zika Virus
Specialty populations
- Maternal
- Newborns and Infants
- Pediatrics, Adolescents
- Geriatrics
- Immunodeficient
Study and vaccine types
- Combination vaccines
- BARDA-funded studies
- First-in-human studies